Share on StockTwits

Furiex Pharmaceuticals (NASDAQ:FURX) CFO Sailash Patel unloaded 32,928 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $104.00, for a total value of $3,424,512.00. Following the transaction, the chief financial officer now directly owns 26,444 shares of the company’s stock, valued at approximately $2,750,176. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Furiex Pharmaceuticals (NASDAQ:FURX) traded up 0.69% during mid-day trading on Thursday, hitting $104.85. 133,816 shares of the company’s stock traded hands. Furiex Pharmaceuticals has a 52 week low of $32.05 and a 52 week high of $121.97. The stock’s 50-day moving average is $104.2 and its 200-day moving average is $81.95. The company’s market cap is $1.133 billion.

Furiex Pharmaceuticals (NASDAQ:FURX) last released its earnings data on Wednesday, May 7th. The company reported ($1.25) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.63) by $0.62. The company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $10.01 million. During the same quarter last year, the company posted $0.82 earnings per share. Furiex Pharmaceuticals’s revenue was down 83.7% compared to the same quarter last year. On average, analysts predict that Furiex Pharmaceuticals will post $-2.27 earnings per share for the current fiscal year.

Furiex Pharmaceuticals, Inc is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.